Mounjaro weight loss injection: List of people who qualify and how it works
The drug is an antidiabetic drug which lowers blood sugar levels and and slows down how quickly food is digested. Mounjaro will be prescribed to severely overweight people who also suffer from a range of other health problems. It will be made by Lilly, through the NHS over the next three years.
In the first year of the programme, the drug will be offered to people with a body mass index (BMI) score of over 40 who have at least four other health problems linked to obesity, such as type 2 diabetes, high blood pressure, heart disease and obstructive sleep apnoea.
READ MORE: New 'Frankenstein' Covid 'Stratus' strain 'soaring in UK' has one unique symptom
READ MORE: Crime boss' wife 'forced to live in a tent' when their illegal scrap yard is closed down
Dr Claire Fuller, from NHS England, said: 'This is an important next step in the rollout of weight loss drugs, with community-based services now able to offer this treatment from today.
'We urgently need to address rising levels of obesity and prioritise support for those who are experiencing severe ill health – and greater access to weight loss drugs will make a significant difference to the lives of those people.
'These drugs are an important tool alongside the range of wraparound NHS support and advice on good nutrition and increasing physical activity, which will be vital in helping some people lose weight and reduce their risk of serious long-term conditions.
'While not everyone will be eligible for weight loss drugs, it's important that anyone who is worried about the impact of their weight on their health discusses the range of NHS support available with their healthcare professional.'
National Institute for Health and Care Excellence (NICE) recommends tirzepatide (Mounjaro) for the management of obesity for certain patients.
Tirzepatide comes in the form of an injection which you inject yourself, once a week. Your doctor or nurse will show you how to use it.
Before prescribing tirzepatide, a healthcare professional will talk through the benefits and limitations, including any side effects you might get.
If a drug prescribed for weight loss is recommended, you will need to eat a balanced, reduced calorie diet and take part in physical activity regularly whilst taking the medicine. It is not recommended if you are pregnant or planning to get pregnant, breastfeeding, or if you have certain health conditions.
For those taking the contraceptive pill and using tirzepatide, the NHS recommends using an additional method of contraception, such as a condom, for the first four weeks of treatment and for four weeks after each dose increase as the contraceptive pill may not be absorbed by the body during this time.
Potential side effects of tirzepatide include nausea, vomiting, diarrhoea and constipation, according to the National Institute for Health and Care Excellence.
Estimates suggest around 1.5 million people in the UK are already taking weight loss drugs, which may have been prescribed through specialist weight loss services or via private prescription.
Health Secretary Wes Streeting said: 'Obesity is now one of the leading causes of ill health, costing the NHS billions. Yet we now have the science, technology, and knowledge to end the obesity epidemic, if we seize this opportunity.
'Obesity jabs are used by 1.5 million people in the UK, mainly through private prescriptions. The NHS was founded on a promise to 'universalise the best', and this Government is determined to bring revolutionary modern treatments to everyone who needs them, not just those who can afford to pay.
'This rollout is an important step in making these medicines more widely available, and beginning to shift the focus of healthcare from sickness to prevention, which our forthcoming 10-year plan will deliver.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fast Company
27 minutes ago
- Fast Company
Wegovy and Zepbound prices are dropping but steady access to the weight-loss drugs remains a challenge
Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging. The medications still amount to around $500 per month for those without insurance — out of reach for many patients. And even for people with insurance, coverage remains uneven. 'The medications should be available, the question is at what price and can people sustain that,' said Matt Maciejewski, a Duke University professor who studies obesity treatment coverage. Doctors say the situation forces them to get creative in treating patients, but there's hope that prices may fall more in the future. The drugs are still in high demand Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity. Zepbound brought in $2.3 billion in U.S. sales during this year's first quarter, making it one of drugmaker Eli Lilly's best sellers. Novo Nordisk says Wegovy has about 200,000 weekly prescriptions in the U.S., where it brought in nearly $1.9 billion in first-quarter sales. Insurance coverage is increasing — for some The benefits consultant Mercer says more businesses with 500 or more employees are adding coverage of the injected drugs for their workers and family members. And Novo says 85% of its patients who have coverage in the U.S. pay $25 or less per month. Plus some patients with diabetes can get coverage of the GLP-1 drugs Ozempic and Mounjaro from Novo and Lilly that are approved to treat that condition. But most state and federally funded Medicaid programs don't cover the drugs for obesity and neither does Medicare, the federal program mainly for people age 65 and older. Even the plans that cover the drugs often pay only a portion of the bill, exposing patients to hundreds of dollars in monthly costs, said Dr. Beverly Tchang. Drugmakers offer help with these out-of-pocket costs, but that assistance can be limited. 'Coverage is not the same as access,' said Tchang, a New York-based doctor who serves as a paid advisor to both Novo and Lilly. But coverage remains inconsistent Bill-payers like employers are nervous about drugs that might be used by a lot of people indefinitely. Some big employers have dropped coverage of the drugs due to the expense. Pharmacy benefit managers, or PBMs, also are starting to pick one brand over the other as they negotiate deals with the drugmakers. One of the nation's largest PBMs, run by CVS Health, dropped Zepbound from its national formulary, or list of covered drugs, on July 1 in favor of Wegovy. That forced Tchang to figure out another treatment plan for several patients, many of whom took Zepbound because it made them less nauseous. Dr. Courtney Younglove's office sends prospective patients a video link showing them how to check their insurer's website for coverage of the drugs before they visit. 'Then some of them just cancel their appointment because they don't have coverage,' the Overland Park, Kansas, doctor said. Cheaper compounded drugs are still being sold Compounding pharmacies and other entities were allowed to make off-brand, cheaper copies of Wegovy and Zepbound when there was a shortage of the drugs. But the U.S. Food and Drug Administration determined earlier this year that the shortage had ended. That should have ended the compounded versions, but there is an exception: Some compounding is permitted when a drug is personalized for the patient. The health care company Hims & Hers Health offers compounded doses of semaglutide, the drug behind Wegovy, that adjust dose levels to help patients manage side effects. Hims says these plans start at $165 a month for 12 months, with customers paying in full upfront. It's a contentious issue. Eli Lilly has sued pharmacies and telehealth companies trying to stop them from selling compounded versions of its products. Novo recently ended a short-lived partnership with Hims to sell Wegovy because the telehealth company continued compounding. Novo says the compounded versions of its drug put patient safety at risk because ingredients are made by foreign suppliers not monitored by US regulators. Hims says it checks all ingredients to make sure they meet U.S. quality and safety standards. It also uses a third-party lab to verify that a drug's strength is accurately labeled. Prices have dropped Both drugmakers are selling most of their doses for around $500 a month to people without insurance, a few hundred dollars less than some initial prices. Even so, that expense would eat up about 14% of the average annual per person income in the U.S., which is around $43,000. There are some factors that may suppress prices over time. Both companies are developing pill versions of their treatments. Those could hit the market in the next year or so, which might drive down prices for the older, injectable doses. Younglove said some of her patients save as much as 15% by getting their doses shipped from a pharmacy in Canada. They used to get them from an Israeli pharmacy until the Canadians dropped their prices. She says competition like this, plus the introduction of pill versions, will pressure U.S. prices. 'I think price wars are going to drive it down,' she said. 'I think we are in the early stages. I have hope.' The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group. The AP is solely responsible for all content.
Associated Press
28 minutes ago
- Associated Press
American kids have become increasingly unhealthy over nearly two decades, new study finds
The health of U.S. children has deteriorated over the past 17 years, with kids today more likely to have obesity, chronic diseases and mental health problems like depression, a new study says. Much of what researchers found was already known, but the study paints a comprehensive picture by examining various aspects of children's physical and mental health at the same time. 'The surprising part of the study wasn't any with any single statistic; it was that there's 170 indicators, eight data sources, all showing the same thing: a generalized decline in kids' health,' said Dr. Christopher Forrest, one of the authors of the study published Monday in the Journal of the American Medical Association. Health Secretary Robert F. Kennedy Jr. has brought children's health to the forefront of the national policy conversation, unveiling in May a much-anticipated 'Make America Healthy Again' report that described kids as undernourished and overmedicated, and raised concerns about their lack of physical activity. But the Trump administration's actions — including cuts to federal health agencies, Medicaid and scientific research — are not likely to reverse the trend, according to outside experts who reviewed Monday's study. 'The health of kids in America is not as good as it should be, not as good as the other countries, and the current policies of this administration are definitely going to make it worse,' said Dr. Frederick Rivara, a pediatrician and researcher at the Seattle Children's Hospital and UW Medicine in Seattle. He co-authored an editorial accompanying the new study. Forrest and his colleagues analyzed surveys, electronic health records from 10 pediatric health systems and international mortality statistics. Among their findings: The research points to bigger problems with America's health, said Forrest, who is a pediatrician at the Children's Hospital of Philadelphia. 'Kids are the canaries in the coal mine,' he said. ' When kids' health changes, it's because they're at increased vulnerability, and it reflects what's happening in society at large.' The timing of the study, he said, is 'completely fortuitous.' Well before the 2024 presidential election, Forrest was working on a book about thriving over the life span and couldn't find this sort of comprehensive data on children's health. The datasets analyzed have some limitations and may not be applicable to the full U.S. population, noted Dr. James Perrin, a pediatrician and spokesman for the American Academy of Pediatrics, who wasn't involved in the study. 'The basic finding is true,' he said. The editorial published alongside the study said while the administration's MAHA movement is bringing welcome attention to chronic diseases, 'it is pursuing other policies that will work against the interests of children.' Those include eliminating injury prevention and maternal health programs, canceling investments in a campaign addressing sudden infant death and 'fueling vaccine hesitancy among parents that may lead to a resurgence of deadly vaccine-preventable diseases,' authors wrote. Officials from the U.S. Health and Human Services Department did not respond to a request for comment. Forrest said risks highlighted by the MAHA report, such as eating too much ultra-processed food, are real but miss the complex reality driving trends in children's health. 'We have to step back and take some lessons from the ecological sustainability community and say: Let's look at the ecosystem that kids are growing up in. And let's start on a kind of neighborhood-by-neighborhood, city-by-city basis, examining it,' he said. ____ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Yahoo
an hour ago
- Yahoo
Measles outbreak leaves several children ‘seriously unwell' as alert issued by NHS
A measles outbreak on Merseyside has left several children 'seriously unwell', a top NHS hospital has warned as it urged people to get vaccinated to help combat the spread of the disease. The rise in cases, according to an alert on Alder Hey Children's Hospital websites, is also driving an increase in patients attending its A&E. In an open letter, published on Monday, the trust's senior directors warned: 'Measles is putting children and young people at risk within our communities and our hospital. Several children are seriously unwell and receiving treatment at Alder Hey Children's Hospital. 'Measles is on the rise amongst our children. We can all help stop it. Get vaccinated now.' It warned that the reason there are more cases of the virus is because fewer people are having the Measles, Mumps and Rubella (MMR) vaccine. The trust said the number of children being treated at Alder Hey hospital over measles is increasing and warned 'children in hospital who are very poorly for another reason, are at higher risk of catching the virus.' In a separate, now-deleted post on its website, Alder Hey said it was experiencing high levels of A&E attendances and that it was 'seeing an increase in children presenting with symptoms of measles.' Measles is highly contagious and, in rare cases, can be fatal. Symptoms usually begin with a runny nose, sneezing, coughing and a high temperature. A measles rash follows a few days after, starting on the face and behind the ears before spreading to the rest of the body. The virus can also cause red, sore eyes. From 26 May to 29 June, there were 133 cases of measles reported to the UK Health Security Agency. Last month UK Health Security Agency published a warning over continued outbreaks and the risk of infection on holiday after data showed 420 measles cases were reported in England between January and May 2025. The majority of those cases, 66 per cent, were in children aged 10 years and under. London had the highest number of cases overall in 2025, with 162. In the four weeks to 5 June, 19 cases, 25 per cent, were reported in the North West and 11 per cent in the West Midlands. #Measles is highly infectious. One person with measles can infect up to 15 others! The best way to protect against measles and stay safe is to have 2 doses of the MMR vaccine. Here's Consultant in Paediatric Public Health at Alder Hey, Rachel Isba, to tell you more: — 🏥 Alder Hey 💙 (@AlderHey) July 6, 2025 Liverpool City Council published a plea on 4 July to parents to get children vaccinated amid a rise in cases across Merseyside. In the warning, Dr Merav Kliner, deputy director for UK Health Security Agency in the North West said: 'With declines in childhood vaccine uptake, including MMR, observed in many countries around the world over the last decade, exacerbated by the COVID-19 pandemic, we are now seeing the impact of this with large measles outbreaks globally including recently in Europe and England last year.' 'Measles is one of the most highly infectious diseases and spreads rapidly among those who are unvaccinated and is often the canary in the coalmine for vaccine preventable diseases. 'We are concerned that this could be an early warning sign of other possible disease outbreaks both globally and here at home, especially over the summer months as families with unvaccinated children and adults travel to countries where diseases are endemic or outbreaks are occurring.'
